Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus

被引:98
作者
Weill, Alain [1 ]
Paita, Michel [1 ]
Tuppin, Philippe [1 ]
Fagot, Jean-Paul [1 ]
Neumann, Anke [1 ]
Simon, Dominique [2 ,3 ]
Ricordeau, Philippe [1 ]
Montastruc, Jean-Louis [4 ,6 ,7 ]
Allemand, Hubert [5 ]
机构
[1] Caisse Natl Assurance Malad, Direct Strategie Etud & Stat, F-75986 Paris 20, France
[2] Grp Hosp Pitie Salpetriere, Serv Diabetol, F-75634 Paris, France
[3] INSERM, Ctr Rech Epidemiol & Sante Populat, Villejuif, France
[4] Fac Med Toulouse, Toulouse, France
[5] Caisse Natl Assurance Malad, Direct Gen, F-75986 Paris 20, France
[6] Ctr Hosp Univ, INSERM, Toulouse, France
[7] Ctr Hosp Univ, Serv Pharmacol Clin, Unite Pharmacoepidemiol, EA 3696, Toulouse, France
关键词
benfluorex; valvular heart disease; adverse effects; health insurance system; reimbursement databases; pharmacoepidemiology; APPETITE-SUPPRESSANT DRUGS; 5-HT2B RECEPTORS; FENFLURAMINE; DATABASES; PATIENT; FRANCE; RISK;
D O I
10.1002/pds.2044
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose To evaluate and quantify in diabetic patients treated with benfluorex in France, a fenfluramine-derivated product, a possible increase in risk of valvular heart disease, previously suggested by several published case reports. Methods This was a French comparative cohort study using data from two large national linked databases, health insurance system (SNIIRAM) and hospitalization (PMSI). Patients aged 40-69 years with reimbursement for oral antidiabetic and/or insulin in 2006 were eligible. Exposed patients were defined as patients with at least one benfluorex reimbursement in 2006. Selected admission diagnoses of interest in 2007 and 2008 PMSI databases were valvular insufficiency for any cause, mitral insufficiency, aortic insufficiency, and valvular replacement surgery with cardiopulmonary bypass. Relative risks (RR) were adjusted on gender, age, and history of chronic cardiovascular disease. Results A total of 1 048 173 diabetic patients were included, with 43 044 (4.1%) exposed to benfluorex. The risk of hospitalization in 2007 and 2008 for any cardiac valvular insufficiency was higher in the benfluorex group: crude RR = 2.9 [95% confidence interval 2.2-3.7] and adjusted RR = 3.1 [2.4-4.0], with a lower risk for patients with lower cumulative dose of benfluorex. Adjusted RR for mitral insufficiency and aortic insufficiency admissions were 2.5 [1.9-3.7] and 4.4 [3.0-6.6], respectively. Adjusted RR for valvular replacement surgery was 3.9 [2.6-6.1]. Conclusions Benfluorex in diabetic patients was significantly associated with hospitalization for valvular heart disease in the 2 years following benfluorex exposure. Linkage between SNIIRAM and PMSI databases is in France a valuable tool to quantify the risk of serious adverse drug reactions. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:1256 / 1262
页数:7
相关论文
共 27 条
[1]   Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].
Abenhaim, L ;
Moride, Y ;
Brenot, F ;
Rich, S ;
Benichou, J ;
Kurz, X ;
Higenbottam, T ;
Oakley, C ;
Wouters, E ;
Aubier, M ;
Simonneau, G ;
Begaud, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616
[2]  
[Anonymous], 2009, B EPIDEMIOL HEBD
[3]   Drug-induced fibrotic valvular heart disease [J].
Bhattacharyya, Sanjeev ;
Schapira, Anthony H. ;
Mikhailidis, Dimitri P. ;
Davar, Joseph .
LANCET, 2009, 374 (9689) :577-585
[4]   Fenfluramine-like cardiovascular side-effects of benfluorex [J].
Boutet, K. ;
Frachon, I. ;
Jobic, Y. ;
Gut-Gobert, C. ;
Leroyer, C. ;
Carlhant-Kowalski, D. ;
Sitbon, O. ;
Simonneau, G. ;
Humbert, M. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (03) :684-688
[5]   Valvular heart disease associated with fenfluramine-phentermine [J].
Connolly, HM ;
Crary, JL ;
McGoon, MD ;
Hensrud, DD ;
Edwards, BS ;
Edwards, WD ;
Schaff, HV .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588
[6]  
Connolly HM, 1997, NEW ENGL J MED, V337, P1783
[7]   Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France [J].
Elalamy, Ismail ;
Le Gal, Gregoire ;
Nachit-Ouinekh, Fatima ;
Lafuma, Antoine ;
Emery, Corinne ;
Le-Fur, Camille ;
Chapuis, Francois .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2009, 15 (04) :428-434
[8]  
Fitzgerald LW, 2000, MOL PHARMACOL, V57, P75
[9]   Benfluorex and Unexplained Valvular Heart Disease: A Case-Control Study [J].
Frachon, Irene ;
Etienne, Yves ;
Jobic, Yannick ;
Le Gal, Gregoire ;
Humbert, Marc ;
Leroyer, Christophe .
PLOS ONE, 2010, 5 (04) :1-5
[10]   A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation [J].
Jick, H ;
Vasilakis, C ;
Weinrauch, LA ;
Meier, CR ;
Jick, SS ;
Derby, LE .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (11) :719-724